Impact of oral iron supplementation on first-time whole blood donors deferred due to low haemoglobin.

Background And Objectives: Low haemoglobin (Hb) in whole blood donors account for 15.5% to 55.8% deferrals which is easily treatable.

Efficacy and Safety of Higher Doses of Levofloxacin for MDR-TB: A Randomized Placebo-controlled Phase 2 Trial.

Background: Evaluation of optimal dosing has generally been inadequate during TB drug development. Fluoroquinolones are central to TB treatment. We aimed to determine the dose of levofloxacin needed to achieve maximal efficacy and acceptable safety and tolerability as part of a multidrug TB regimen.

DFT investigation of 5-fluorouracil tautomerism and non-covalent interactions with PLGA nanoparticles for enhanced drug delivery and sensing.

This study investigates the non-covalent interactions between both the free and tautomeric forms of 5-fluorouracil (5-FU) and poly(lactic-co-glycolic acid) (PLGA) nanoparticles through density functional dispersion correction (DFT-D) at the B3LYP-D level in a dichloromethane (DCM) and water environments. Our results indicate that the non-covalent interactions formed between the carbonyl and amide groups of the free form of 5-FU and the carboxyl group of PLGA facilitate a rapid initial release of the drug, aligning with experimental findings. The calculated binding energies for 5-FU in its keto-enol (-0.

Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial.

Background: Current guidelines for the treatment of multidrug-resistant/rifampin-resistant tuberculosis (MDR/RR-TB) are based on clinical trials evaluating fixed duration regimens. However, when a regimen succeeds, it remains unknown whether a shorter duration could yield the same results. Similarly, if a regimen fails, it is unclear whether extending the treatment could improve outcomes.

The R337C mutation in the p53 oligomerization domain affects the regulatory domain and its ability to bind response elements: Evidence based on structural and biophysical studies.

The homotetrameric form of p53 is critical for performing essential functions like maintaining genomic stability and preventing uncontrolled cell proliferation. In part, these crucial functions are mediated by the p53 C-terminal region (CTR) containing the tetramerization/oligomerization domain (TD/OD) and regulatory domain (RD) responsible for the protein's oligomeric state and regulating the p53 function. Mutations in the tetramerization domain decrease the transactivation potential and alter the transactivation specificity of p53.